Lost Money on TriSalus Life Sciences, Inc. (TLSI)? Possible Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - May 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:TLSI) concerning potential violations of the federal securities laws.

TLSI reported Q1 2026 revenue of $8.9 million. Wall Street consensus had projected $9.4 million -- a shortfall of approximately $500,000, or more than 5%. The miss arrived approximately two months after CEO Mary Szela reaffirmed full-year 2026 revenue guidance of $60 million to $62 million on the Q4 2025 earnings call on March 5, 2026.

Alongside the Q1 miss, the company cut its full-year 2026 revenue outlook to $54 million to $57 million -- a reduction of up to $8 million from the range reaffirmed in March 2026. The revised midpoint of $55.5 million represented a roughly 9% reduction from the prior midpoint of $61 million.

If you suffered a loss on your TriSalus Life Sciences, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [e-mail] or call [phone] to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[e-mail]
Tel: [phone]
Fax: [phone]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298084

The TriSalus Life Sciences Stock at the time of publication of the news with a raise of +4,29 % to 3,16USD on Nasdaq stock exchange (19. Mai 2026, 21:48 Uhr).

Schreibe Deinen Kommentar